On Tuesday, Novavax, Inc (NASDAQ: NVAX) was -0.30% drop from the session before settling in for the closing price of $6.75. A 52-week range for NVAX has been $5.01 – $15.22.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 25.88%. When this article was written, the company’s average yearly earnings per share was at 294.54%. With a float of $147.56 million, this company’s outstanding shares have now reached $161.96 million.
Let’s determine the extent of company efficiency that accounts for 952 employees. In terms of profitability, gross margin is 88.25%, operating margin of 32.78%, and the pretax margin is 38.93%.
Novavax, Inc (NVAX) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Novavax, Inc stocks. The insider ownership of Novavax, Inc is 8.90%, while institutional ownership is 57.65%. The most recent insider transaction that took place on May 19 ’25, was worth 75,883. Before that another transaction happened on Apr 14 ’25, when Company’s Former Director proposed sale 4,000 for $6.10, making the entire transaction worth $24,406.
Novavax, Inc (NVAX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 294.54% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 37.02% during the next five years compared to 25.88% growth over the previous five years of trading.
Novavax, Inc (NASDAQ: NVAX) Trading Performance Indicators
You can see what Novavax, Inc (NVAX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.03. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.87.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.65, a number that is poised to hit -0.04 in the next quarter and is forecasted to reach -0.00 in one year’s time.
Technical Analysis of Novavax, Inc (NVAX)
Looking closely at Novavax, Inc (NASDAQ: NVAX), its last 5-days average volume was 5.13 million, which is a drop from its year-to-date volume of 6.42 million. As of the previous 9 days, the stock’s Stochastic %D was 15.27%.
During the past 100 days, Novavax, Inc’s (NVAX) raw stochastic average was set at 45.62%, which indicates a significant increase from 17.66% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.35 in the past 14 days, which was lower than the 0.44 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.95, while its 200-day Moving Average is $7.77.
